# Immatics

Source: https://onco.cc/companies/immatics/  
OnCo record `immatics` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

TCR-T company whose PRAME-directed anzu-cel (IMA203) is in the phase 3 SUPRAME trial in melanoma, with a launch targeted for 2027.

## Summary

Immatics, based in Tübingen and Houston and listed as IMTX, is a TCR-T company whose PRAME-directed anzu-cel, or IMA203, is in the phase 3 SUPRAME trial in melanoma, with a launch targeted for 2027. In its phase 1b, anzu-cel gave a 54 percent confirmed response rate with a median duration of response of 12.1 months in PD-1-pretreated melanoma; SUPRAME, with a progression-free survival primary endpoint, is on track to complete randomisation by the end of 2026 with its analysis expected to trigger in 2026, and the company also develops TCR bispecifics it calls TCER. OnCo links it to melanoma and sarcomas, to TCR-T cell therapy, to PRAME as a target, and to the Comprehensive Cancer Center Tübingen-Stuttgart. Whether an engineered TCR therapy can become a standard option in a common solid tumour is the question SUPRAME will answer. The PRAME target page carries the competitive field.

## Fields

- Kind: Company
- Last checked: 2026-09-04
- HQ: Tübingen / Houston
- Type: cell-therapy
- Website: https://immatics.com
- Ticker: IMTX

## Sources

- Q2 2026 update: https://www.globenewswire.com/news-release/2026/08/18/3346680/0/en/immatics-announces-second-quarter-2026-financial-results-and-business-update.html

## Connected records

- cancers: [Melanoma](https://onco.cc/cancers/melanoma/), [Sarcomas (soft tissue, bone, GIST)](https://onco.cc/cancers/sarcoma/)
- fronts: [Cell Therapy](https://onco.cc/fronts/cell-therapy/)
- technologies: [TCR-T cell therapy](https://onco.cc/technologies/tcr-t/)
- drugs: [IMA203](https://onco.cc/drugs/ima203/)
- trials: [ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors](https://onco.cc/trials/nct03686124/), [IMA402 T Cell-Engaging Receptor Molecule (TCER®) in Recurrent and/or Refractory Solid Tumors](https://onco.cc/trials/nct05958121/), [SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma](https://onco.cc/trials/nct06743126/)
- targets: [PRAME](https://onco.cc/targets/prame/)
- ideas: [Antibodies that see mutant KRAS and p53 fragments displayed on the cell surface](https://onco.cc/ideas/idea-bio1-pmhc-bispecifics-public-drivers/)
- institutions: [Comprehensive Cancer Center Tübingen-Stuttgart](https://onco.cc/institutions/ccc-tuebingen/)

---
JSON: https://onco.cc/api/v1/entities/immatics.json